Concurrent Investment Advisors LLC Makes New $350,000 Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Concurrent Investment Advisors LLC acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,582 shares of the medical equipment provider's stock, valued at approximately $350,000.

Several other large investors have also recently made changes to their positions in LNTH. Jones Financial Companies Lllp grew its position in shares of Lantheus by 108.3% in the 4th quarter. Jones Financial Companies Lllp now owns 2,273 shares of the medical equipment provider's stock valued at $203,000 after buying an additional 1,182 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Lantheus by 13.4% during the fourth quarter. Victory Capital Management Inc. now owns 87,130 shares of the medical equipment provider's stock worth $7,795,000 after buying an additional 10,297 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Lantheus during the fourth quarter worth about $36,183,000. Amundi grew its holdings in shares of Lantheus by 529.5% during the fourth quarter. Amundi now owns 176,952 shares of the medical equipment provider's stock worth $16,633,000 after buying an additional 148,842 shares during the last quarter. Finally, Daiwa Securities Group Inc. purchased a new position in shares of Lantheus during the fourth quarter worth about $136,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LNTH has been the subject of a number of recent analyst reports. B. Riley reduced their price objective on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research report on Monday, June 23rd. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, Truist Financial decreased their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $131.20.

Lantheus Price Performance

Shares of Lantheus stock traded down $1.76 during mid-day trading on Tuesday, reaching $81.30. 569,910 shares of the stock were exchanged, compared to its average volume of 972,619. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49. The company has a market cap of $5.62 billion, a price-to-earnings ratio of 23.10 and a beta of 0.12. Lantheus Holdings, Inc. has a fifty-two week low of $73.11 and a fifty-two week high of $126.89. The firm has a 50-day simple moving average of $80.26 and a 200 day simple moving average of $89.91.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The firm's revenue was up .8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.69 EPS. On average, sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the sale, the director directly owned 318,650 shares in the company, valued at $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.00% of the stock is currently owned by company insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.